Atlas Trials

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Clinical trial NCT06664021 · RECRUITING

Trial details

NCT number
NCT06664021
Sponsor
Anhui Provincial Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Intrahepatic Cholangiocarcinoma
Start date
2024-11-16
Primary completion
2026-12-30
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.